Tech Company Financing Transactions

Argos Therapeutics Funding Round

Pharmstandard, Aurora Funds and Intersouth Partners participated in a $42.5 million funding round for Argos Therapeutics. The financing closed on 8/26/2013.

Transaction Overview

Company Name
Announced On
8/26/2013
Transaction Type
Venture Equity
Amount
$42,500,000
Round
Undisclosed
Investors

Pharmstandard (Lead Investor)

Aurora Funds (Jeffrey Clark)

Intersouth Partners (Philip Tracy)

Proceeds Purpose
The money will be used to fund a Phase 3 study -- the final phase required by regulators before seeking approval to put a drug on the market -- that was launched in January and ultimately is expected to include 450 patients.

Company Information

Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
4233 Technology Dr.
Durham, NC 27704
USA
Email Address
Overview
Argos Therapeutics is a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases based on its Arcelis technology platform.
Profile
Argos Therapeutics LinkedIn Company Profile
Social Media
Argos Therapeutics Company Twitter Account
Company News
Argos Therapeutics News
Facebook
Argos Therapeutics on Facebook
YouTube
Argos Therapeutics on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Jeffrey Abbey
  Jeffrey Abbey LinkedIn Profile  Jeffrey Abbey Twitter Account  Jeffrey Abbey News  Jeffrey Abbey on Facebook
Chief Financial Officer
Richard Katz
  Richard Katz LinkedIn Profile  Richard Katz Twitter Account  Richard Katz News  Richard Katz on Facebook
Chief Scientific Officer
Charles Nicolette
  Charles Nicolette LinkedIn Profile  Charles Nicolette Twitter Account  Charles Nicolette News  Charles Nicolette on Facebook
VP - Finance
Lori Harrelson
  Lori Harrelson LinkedIn Profile  Lori Harrelson Twitter Account  Lori Harrelson News  Lori Harrelson on Facebook


 

 

Browse more venture capital transactions:

Prev: 8/26/2013: DisruptiveApps venture capital transaction
Next: 8/26/2013: Solexel venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. VC investment data records on this site are sourced from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary